Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Identify first generic entrants

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 6,488,962

« Back to Dashboard

Which drugs does patent 6,488,962 protect, and when does it expire?

Patent 6,488,962 protects JENTADUETO XR, XARTEMIS XR, PROQUIN XR, GRALISE, GLUMETZA, and SYNJARDY XR, and is included in six NDAs. There have been zero Paragraph IV challenges on Xartemis XR, Gralise, and Glumetza. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 6,488,962

Title: Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Abstract:The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
Inventor(s): Berner; Bret (El Granada, CA), Louie-Helm; Jenny (Union City, CA)
Assignee: DepoMed, Inc. (Menlo Park, CA)
Application Number:09/598,061
Patent Claim Types:
see list of patent claims
Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016RXYesNo6,488,962► SubscribeY
Boehringer Ingelheim
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016RXYesYes6,488,962► SubscribeY
Mallinckrodt Inc
acetaminophen; oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL204031-001Mar 11, 2014RXYesYes6,488,962► SubscribeY
Depomed Inc
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005DISCNNoNo6,488,962► SubscribeY
Depomed Inc
TABLET;ORAL022544-001Jan 28, 2011RXYesYes6,488,962► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,488,962

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2213108► Subscribe
Israel153464► Subscribe
European Patent Office1294363► Subscribe
Denmark1294363► Subscribe
Germany60101581► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.